Novartis, a global pharmaceutical company announced that the U.S. FDA has approved Entresto (sacubitril/valsartan) for the treatment of heart failure with reduced ejection fraction. The approval is based on the promising results from the PARADIGM-HF clinical trial, the largest heart failure trial involving 8,442 patients. The trial was stopped early because it has shown that Entresto when compared with ACE-inhibitor enalapril significantly reduced the risk of cardiovascular death. Entresto is an ARNI (angiotensin receptor neprilysin inhibitor) that reduces the strain on the failing heart and is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other angiotensin receptor blocker. Approximately 6 million people in the US suffer from heart failure and half of this population has reduced ejection fraction form. The approval of Entresto will increase the life span and reduce the hospitalization for this group of patients.